{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/dpp-4-inhibitors/","result":{"pageContext":{"chapter":{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors","depth":2,"htmlHeader":"<!-- begin field 86002b92-8e5f-497f-9cd3-0f2abb4b27c4 --><h2>DPP-4 inhibitors</h2><!-- end field 86002b92-8e5f-497f-9cd3-0f2abb4b27c4 -->","summary":"","htmlStringContent":"<!-- begin item 7b0202da-c782-4852-a3cc-4b04725ea9b0 --><!-- end item 7b0202da-c782-4852-a3cc-4b04725ea9b0 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"c02894e9-2b86-59ef-952d-911c78c519a8","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field c5a96ac2-f435-4063-891e-5d9092d6ebe4 --><h3>Recommended doses</h3><!-- end field c5a96ac2-f435-4063-891e-5d9092d6ebe4 -->","summary":"","htmlStringContent":"<!-- begin item 873cacdb-9a3e-4f54-bafc-506cf4b6dfe2 --><!-- begin field b4f58675-73a9-4ba6-8635-d104f040ba3d --><p><strong>There are currently five DPP-4 inhibitors available in the UK.</strong></p><ul><li><strong>For adults over 18 years of age:</strong><ul><li>Alogliptin: 25 mg once daily.</li><li>Linagliptin: 5 mg once daily.</li><li>Sitagliptin: 100 mg once daily.</li><li>Saxagliptin: 5 mg once daily.</li><li>Vildagliptin: 50 mg twice daily. When used in dual combination with a sulfonylurea, reduce to 50 mg once daily in the morning.</li></ul></li><li><strong>In people with renal impairment:</strong><ul><li>Alogliptin: 12.5 mg once daily if estimated glomerular filtration rate (eGFR) is 30–50 mL/minute/1.73 m<sup>2</sup>. Reduce to 6.25 mg once daily if eGFR is less than 30 mL/minute/1.73 m<sup>2</sup>.</li><li>Linagliptin: no dose adjustment is required.</li><li>Saxagliptin: 2.5 mg once daily in moderate to severe renal impairment.</li><li>Sitagliptin: 50 mg once daily if eGFR is 30–45 mL/minute/1.73 m<sup>2</sup>. Reduce to 25 mg once daily if eGFR is less than 30 mL/minute/1.73 m<sup>2</sup>.</li><li>Vildagliptin: 50 mg once daily if eGFR is less than 50 mL/minute/1.73 m<sup>2</sup>.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field b4f58675-73a9-4ba6-8635-d104f040ba3d --><!-- end item 873cacdb-9a3e-4f54-bafc-506cf4b6dfe2 -->","subChapters":[]},{"id":"1d592c49-393d-51d0-bcc0-c62c138e0437","slug":"initiating-monitoring","fullItemName":"Initiating and monitoring","depth":3,"htmlHeader":"<!-- begin field 4b5dc81f-b635-4836-8205-9d477f40b33d --><h3>Initiating and monitoring</h3><!-- end field 4b5dc81f-b635-4836-8205-9d477f40b33d -->","summary":"","htmlStringContent":"<!-- begin item 9597b4ca-50e7-48bb-bb7a-6b56cca7b0ac --><!-- begin field 836fb9f1-509b-4fb1-8103-e14f6a8031b3 --><ul><li><strong>Before starting treatment with saxagliptin, vildagliptin, or alogliptin:</strong><ul><li>Check liver and kidney function. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/prescribing-information/dpp-4-inhibitors/#contraindications-cautions\">Contraindications and cautions</a> for more information.</li></ul></li><li><strong>During treatment with:</strong><ul><li>Vildagliptin: monitor liver function at 3-monthly intervals during the first year, and periodically thereafter.<ul><li>If the person develops increased transaminase levels, repeat liver function tests (LFTs) and monitor until results normalize. </li></ul></li><li>Saxagliptin: monitor renal function periodically.</li><li>Alogliptin: monitor renal function periodically.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 836fb9f1-509b-4fb1-8103-e14f6a8031b3 --><!-- end item 9597b4ca-50e7-48bb-bb7a-6b56cca7b0ac -->","subChapters":[]},{"id":"2165cc52-21c1-51ef-8631-4354451248ab","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field ee4a1958-16fc-47d2-8a26-19f8e79f62ce --><h3>Contraindication and cautions</h3><!-- end field ee4a1958-16fc-47d2-8a26-19f8e79f62ce -->","summary":"","htmlStringContent":"<!-- begin item aa8a3fa8-b063-4305-9bc2-a40ca960faf9 --><!-- begin field bb424dae-edfd-4577-98fa-3b1d1f61dc80 --><ul><li><strong>Do not prescribe a DPP-4 inhibitor to people with:</strong><ul><li>Ketoacidosis.</li><li>Hepatic impairment — avoid vildagliptin; avoid saxagliptin and alogliptin if severe hepatic impairment.</li><li>Heart failure — avoid vildagliptin if severe heart failure; avoid alogliptin if moderate-to-severe heart failure.</li></ul></li><li><strong>Prescribe a DPP-4 inhibitor with caution to people:</strong><ul><li>With renal impairment — use saxagliptin with caution in severe renal impairment.</li><li>With hepatic impairment — use saxagliptin with caution in moderate hepatic impairment.</li><li>With a history of pancreatitis (alogliptin, saxagliptin, vildagliptin).</li><li>Heart failure — use saxagliptin with caution if moderate-to-severe heart failure.</li><li>Who are elderly — use saxagliptin with caution.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field bb424dae-edfd-4577-98fa-3b1d1f61dc80 --><!-- end item aa8a3fa8-b063-4305-9bc2-a40ca960faf9 -->","subChapters":[]},{"id":"c92d7ec4-188b-5d4e-a68f-39f07e25b247","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field d836b16f-17fa-48ad-8bac-8727a968c942 --><h3>Adverse effects</h3><!-- end field d836b16f-17fa-48ad-8bac-8727a968c942 -->","summary":"","htmlStringContent":"<!-- begin item 3c4459b1-9250-43b4-b789-df7e5695f477 --><!-- begin field 5de19172-f212-4788-bb4d-ee6b70a4ef77 --><p><strong>Possible adverse effects of DPP-4 inhibitors include:</strong></p><ul><li>Gastrointestinal — constipation, vomiting, nausea, diarrhoea, dyspepsia, gastritis, and gastro-oesophageal reflux (common). </li><li>Acute pancreatitis (uncommon).<ul><li>Advise to seek urgent medical assessment if the person develops jaundice or other signs suggestive of liver dysfunction (such as nausea, vomiting, abdominal pain, fatigue, and dark urine), and stop treatment.</li></ul></li><li>Hepatic — hepatitis and hepatic failure (with vildagliptin and alogliptin, rare).</li><li>Nervous system — headache, dizziness, and tremor (common with sitagliptin, saxagliptin, vildagliptin, and alogliptin).</li><li>Skin — pruritus, angioedema, rash, urticaria, cutaneous vasculitis, and Stevens-Johnson syndrome.</li><li>Musculoskeletal — back pain, arthralgia, myalgia, and arthropathy (with sitagliptin and saxagliptin).</li><li>Infections — increased risk with saxagliptin, alogliptin, and vildagliptin.</li><li>Hypersensitivity reactions (including anaphylaxis) have been reported with sitagliptin, saxagliptin, linagliptin, and alogliptin.</li><li>Other adverse effects include:<ul><li>For sitagliptin: interstitial lung disease, impaired renal function, thrombocytopaenia, and acute renal failure.</li><li>For saxagliptin: erectile dysfunction, peripheral oedema, dyslipidaemia, and hypertriglyceridaemia.</li></ul><ul><li>For linagliptin: nasopharyngitis, cough, and increased amylase levels.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 5de19172-f212-4788-bb4d-ee6b70a4ef77 --><!-- end item 3c4459b1-9250-43b4-b789-df7e5695f477 -->","subChapters":[]},{"id":"c4cbaa60-ca12-5c25-888c-0bf7fa53134c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 4c164221-b6e9-4d78-ad87-bb57c211214a --><h3>Drug interactions</h3><!-- end field 4c164221-b6e9-4d78-ad87-bb57c211214a -->","summary":"","htmlStringContent":"<!-- begin item 80672997-8a32-4918-ab19-3500098d6ee1 --><!-- begin field dd9355a2-e88d-410b-9bfa-f50a72a96d82 --><ul><li><strong>Possible drug interactions associated with DPP-4 inhibitors include: </strong><ul><li>Beta-blockers — the warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment.</li><li>Angiotensin-converting enzyme (ACE) inhibitors — there may be an increased risk of angioedema in people taking vildagliptin and ACE-inhibitors concomitantly.</li><li>Digoxin — sitagliptin increases plasma concentration of digoxin. No dose adjustment of digoxin is recommended, however monitor people at risk of digoxin toxicity.</li><li>Ketoconazole — plasma concentration of saxagliptin may be increased by ketoconazole.</li><li>Rifampicin — effects of linagliptin are possibly reduced by rifampicin.</li><li>Other antidiabetic drugs — the dose of concomitant sulfonylurea may need to be reduced due to an increased risk of hypoglycaemia.</li></ul></li><li><strong>In addition:</strong><ul><li><strong>The blood glucose-lowering effects of </strong><strong>DPP-4 inhibitors may be enhanced by: </strong><ul><li>Alcohol.</li><li>Anabolic steroids.</li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Testosterone. </li></ul></li><li><strong>The blood glucose-lowering effects of </strong><strong>DPP-4 inhibitors may be antagonized by: </strong><ul><li>Corticosteroids. </li><li>Diuretics (thiazide and related, and loop). </li><li>Oestrogens and progestogens.</li></ul></li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field dd9355a2-e88d-410b-9bfa-f50a72a96d82 --><!-- end item 80672997-8a32-4918-ab19-3500098d6ee1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}